News

Asthma is a chronic lung condition affecting approximately 339.4 million people worldwide1, and when uncontrolled, it can be quite debilitating in everyday life. Despite modern-day medicine and the availability of effective treatments, approximately 39% of people with asthma remain uncontrolled1....

Bedfont®, a world leader in breath analysis, announces its acquisition of coVita™, building on 16 years of partnership, market knowledge, and established infrastructure to support global expansion. Bedfont® Scientific Limited, a leading MedTech company with 50 years of experience designing...

World leaders in breath analysis will showcase its Gastrolyzer® range at one of the leading international events for digestive health. Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of industry experience, is pleased to attend this...

Smokerlyzer® registration with Medicah S.A.S in Colombia boosts quit-smoking services in the region. Bedfont® Scientific Limited, an innovative MedTech company with nearly 50 years of experience in the breath analysis industry, is pleased to collaborate with Medicah S.A.S through a...

Bedfont®, a world leader in breath analysis, has been recognised as one of Investec Direct Lending's selected investments for 2025 following Keensight Capital's majority investment in the company. The inclusion highlights Bedfont's position as a leading UK medical technology innovator...

Showcasing the NObreath® and Smokerlyzer® range while connecting with research teams and global distribution partners at Europe's leading respiratory congress. Bedfont® Scientific Limited, a world leader in breath analysis, is excited to be attending this year's European Respiratory Society (ERS)...